List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1667803/publications.pdf Version: 2024-02-01



IAV D RAMAN

#	Article	IF	CITATIONS
1	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009, 115, 1224-1233.	4.1	943
2	Laboratory and Clinical Development of Single Keyhole Umbilical Nephrectomy. Urology, 2007, 70, 1039-1042.	1.0	334
3	Single-Incision, Umbilical Laparoscopic versus Conventional Laparoscopic Nephrectomy: A Comparison of Perioperative Outcomes and Short-Term Measures of Convalescence. European Urology, 2009, 55, 1198-1206.	1.9	311
4	AROMATASE INHIBITORS FOR MALE INFERTILITY. Journal of Urology, 2002, 167, 624-629.	0.4	305
5	Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU International, 2011, 107, 1059-1064.	2.5	283
6	Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2009, 27, 612-618.	1.6	260
7	INCREASED INCIDENCE OF TESTICULAR CANCER IN MEN PRESENTING WITH INFERTILITY AND ABNORMAL SEMEN ANALYSIS. Journal of Urology, 2005, 174, 1819-1822.	0.4	251
8	Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative Chemotherapy. European Urology, 2010, 58, 581-587.	1.9	227
9	Preoperative Hydronephrosis, Ureteroscopic Biopsy Grade and Urinary Cytology Can Improve Prediction of Advanced Upper Tract Urothelial Carcinoma. Journal of Urology, 2010, 184, 69-73.	0.4	221
10	Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU International, 2008, 101, 89-93.	2.5	215
11	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2014, 65, 210-217.	1.9	201
12	Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration. Journal of Urology, 2009, 182, 900-906.	0.4	200
13	Urinary cytology has a poor performance for predicting invasive or highâ€grade upperâ€ŧract urothelial carcinoma. BJU International, 2011, 108, 701-705.	2.5	195
14	Durable oncologic outcomes after radiofrequency ablation. Cancer, 2010, 116, 3135-3142.	4.1	194
15	Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2012, 61, 818-825.	1.9	188
16	Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. Journal of Urology, 2009, 181, 2482-2489.	0.4	186
17	Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder. Clinical Cancer Research, 2005, 11, 8570-8576.	7.0	184
18	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2010, 184, 453-458.	0.4	182

#	Article	IF	CITATIONS
19	Laparoendoscopic single-site surgery in urology: where have we been and where are we heading?. Nature Reviews Urology, 2008, 5, 561-568.	1.4	178
20	Natural History of Residual Fragments Following Percutaneous Nephrostolithotomy. Journal of Urology, 2009, 181, 1163-1168.	0.4	178
21	Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. European Urology, 2019, 75, 18-22.	1.9	169
22	The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy. European Urology, 2012, 61, 245-253.	1.9	168
23	Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. European Urology, 2009, 56, 1-9.	1.9	161
24	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multiâ€institutional analysis of 1363 patients. BJU International, 2009, 103, 307-311.	2.5	160
25	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 2021, 12, 2301.	12.8	159
26	Singleâ€incision laparoscopic surgery: initial urological experience and comparison with naturalâ€orifice transluminal endoscopic surgery. BJU International, 2008, 101, 1493-1496.	2.5	158
27	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. European Urology, 2010, 57, 1072-1079.	1.9	155
28	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European Urology, 2010, 57, 575-581.	1.9	154
29	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. Journal of Urology, 2013, 189, 1662-1669.	0.4	152
30	An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy. Journal of Urology, 2017, 198, 329-334.	0.4	151
31	The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?. European Urology, 2009, 56, 512-519.	1.9	143
32	Testicular Sperm Extraction with Intracytoplasmic Sperm Injection is Successful for the Treatment of Nonobstructive Azoospermia Associated with Cryptorchidism. Journal of Urology, 2003, 170, 1287-1290.	0.4	141
33	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. European Urology, 2014, 65, 650-658.	1.9	134
34	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroâ€ureterectomy. BJU International, 2013, 112, 453-461.	2.5	128
35	Perioperative Outcomes in Patients Undergoing Conventional Laparoscopic Versus Laparoendoscopic Single-site Pyeloplasty. Urology, 2009, 74, 1029-1034.	1.0	126
36	Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU International, 2005, 96, 1031-1035.	2.5	115

#	Article	IF	CITATIONS
37	Advanced patient age is associated with inferior cancerâ€specific survival after radical nephroureterectomy. BJU International, 2010, 105, 1672-1677.	2.5	115
38	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. Journal of Urology, 2012, 188, 398-404.	0.4	114
39	FOXA1, GATA3 and PPARÉ£ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines. Scientific Reports, 2016, 6, 38531.	3.3	112
40	AROMATASE INHIBITORS FOR MALE INFERTILITY. Journal of Urology, 2002, 167, 624-629.	0.4	108
41	Determinants of Quality of Life for Patients With Kidney Stones. Journal of Urology, 2008, 179, 2238-2243.	0.4	106
42	Chronic Kidney Disease Before and After Partial Nephrectomy. Journal of Urology, 2011, 185, 43-48.	0.4	105
43	Robotic radical prostatectomy: operative technique, outcomes, and learning curve. Journal of the Society of Laparoendoscopic Surgeons, 2007, 11, 1-7.	1.1	105
44	Management of patients with upper urinary tract transitional cell carcinoma. Nature Reviews Urology, 2007, 4, 432-443.	1.4	102
45	Complications following prostate needle biopsy requiring hospital admission or emergency department visits – experience from 1000 consecutive cases. BJU International, 2012, 110, 369-374.	2.5	100
46	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. European Urology, 2013, 63, 1082-1090.	1.9	98
47	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymphâ€node density. BJU International, 2009, 103, 302-306.	2.5	93
48	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. European Urology, 2012, 62, 677-684.	1.9	93
49	A delay in radical nephroureterectomy can lead to upstaging. BJU International, 2010, 105, 812-817.	2.5	90
50	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 252-258.	1.6	88
51	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncology, The, 2020, 21, 776-785.	10.7	82
52	Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 904-908.	1.6	80
53	Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 27-32.	1.6	78
54	High-Grade Ureteroscopic Biopsy Is Associated with Advanced Pathology of Upper-Tract Urothelial Carcinoma Tumors at Definitive Surgical Resection. Journal of Endourology, 2012, 26, 398-402.	2.1	75

#	Article	IF	CITATIONS
55	Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU International, 2010, 105, 496-500.	2.5	74
56	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World Journal of Urology, 2017, 35, 337-353.	2.2	74
57	Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. Urology, 2009, 73, 142-146.	1.0	73
58	Ergonomic Considerations of Radical Prostatectomy: Physician Perspective of Open, Laparoscopic, and Robot-Assisted Techniques. Journal of Endourology, 2009, 23, 627-633.	2.1	73
59	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 716-723.	1.6	73
60	Upper urinary tract urothelial carcinoma with locoâ€regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU International, 2011, 108, 1286-1291.	2.5	71
61	Complete Transvaginal NOTES Nephrectomy Using Magnetically Anchored Instrumentation. Journal of Endourology, 2009, 23, 367-371.	2.1	69
62	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 191, 603-610.	0.4	69
63	Role of Magnetic Anchors During Laparoendoscopic Single Site Surgery and NOTES. Journal of Endourology, 2009, 23, 781-786.	2.1	66
64	Inheritance of varicoceles. Urology, 2005, 65, 1186-1189.	1.0	65
65	Impact of Body Mass Index on Cost and Clinical Outcomes After Percutaneous Nephrostolithotomy. Urology, 2008, 72, 756-760.	1.0	64
66	Residual Fragments Following Ureteroscopic Lithotripsy: Incidence and Predictors on Postoperative Computerized Tomography. Journal of Urology, 2012, 188, 2246-2251.	0.4	64
67	General Anesthesia and Contrast-Enhanced Computed Tomography to Optimize Renal Percutaneous Radiofrequency Ablation: Multi-Institutional Intermediate-Term Results. Journal of Endourology, 2009, 23, 1099-1105.	2.1	62
68	Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World Journal of Urology, 2011, 29, 473-480.	2.2	62
69	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology–Young Academic Urologists and theÂUpper Tract Urothelial Carcinoma Collaboration. BJU International, 2018, 121, 252-259	2.5	61
70	Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU International, 2010, 106, 218-223.	2.5	60
71	Residual Fragments After Percutaneous Nephrolithotomy: Cost Comparison of Immediate Second Look Flexible Nephroscopy Versus Expectant Management. Journal of Urology, 2010, 183, 188-193.	0.4	60
72	Obesity Adversely Impacts Disease Specific Outcomes in Patients With Upper Tract Urothelial Carcinoma. Journal of Urology, 2011, 186, 66-72.	0.4	60

#	Article	IF	CITATIONS
73	Adherent perinephric fat at minimally invasive partial nephrectomy is associated with adverse periâ€operative outcomes and malignant renal histology. BJU International, 2016, 117, 636-641.	2.5	60
74	Absence of Viable Renal Carcinoma in Biopsies Performed More Than 1 Year Following Radio Frequency Ablation Confirms Reliability of Axial Imaging. Journal of Urology, 2008, 179, 2142-2145.	0.4	58
75	Assessment of the Minimum Number of Lymph Nodes Needed to Detect Lymph Node Invasion at Radical Nephroureterectomy in Patients With Upper Tract Urothelial Cancer. Urology, 2009, 74, 1070-1074.	1.0	58
76	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2017, 198, 1253-1262.	0.4	58
77	Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma. Journal of Urology, 2012, 187, 845-851.	0.4	57
78	Management options for lower pole renal calculi. Current Opinion in Urology, 2008, 18, 214-219.	1.8	56
79	Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. Urology, 2013, 81, 972-978.	1.0	55
80	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e9-47.e14.	1.6	55
81	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. Annals of Surgical Oncology, 2012, 19, 4337-4344.	1.5	53
82	Increasing body mass index negatively impacts outcomes following robotic radical prostatectomy. Journal of the Society of Laparoendoscopic Surgeons, 2007, 11, 438-42.	1.1	51
83	Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World Journal of Urology, 2011, 29, 495-501.	2.2	50
84	Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU International, 2014, 114, 674-679.	2.5	49
85	Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones. Urological Research, 2011, 39, 141-146.	1.5	46
86	A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. Journal of Urology, 2017, 197, 1208-1213.	0.4	45
87	Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU International, 2011, 108, E304-E309.	2.5	44
88	Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvicalyceal System is Associated With Recurrence-Free and Cancer-Specific Survival: Proposal for a Revision of the Current TNM Classification. European Urology, 2012, 62, 224-231.	1.9	44
89	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. Journal of Urology, 2017, 197, 287-295.	0.4	43
90	Predictors of Cost and Clinical Outcomes of Percutaneous Nephrostolithotomy. Journal of Urology, 2009, 182, 586-590.	0.4	42

#	Article	IF	CITATIONS
91	Current status of renal radiofrequency ablation. Current Opinion in Urology, 2009, 19, 143-147.	1.8	42
92	Complications during the initial experience with laparoendoscopic singleâ€site pyeloplasty. BJU International, 2011, 108, 1326-1329.	2.5	40
93	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. Journal of Urology, 2013, 189, 468-473.	0.4	40
94	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World Journal of Urology, 2013, 31, 5-11.	2.2	39
95	Radiofrequency ablation of small renal cortical tumours in healthy adults: renal function preservation and intermediate oncological outcome. BJU International, 2009, 104, 786-789.	2.5	38
96	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2015, 193, 1486-1493.	0.4	38
97	Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology, 2006, 68, 1268-1274.	1.0	37
98	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 121-130.	2.2	37
99	Synchronous Bilateral Percutaneous Nephrostolithotomy: Analysis of Clinical Outcomes, Cost and Surgeon Reimbursement. Journal of Urology, 2009, 181, 149-153.	0.4	36
100	Intraoperative characterization of arterial vasculature in spermatic cord. Urology, 2004, 64, 561-564.	1.0	35
101	Pathologic Features of Bladder Tumors After Nephroureterectomy or Segmental Ureterectomy for Upper Urinary Tract Transitional Cell Carcinoma. Urology, 2007, 69, 251-254.	1.0	35
102	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2017, 197, 580-589.	0.4	35
103	Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Scientific Reports, 2020, 10, 1439.	3.3	35
104	How Physician and Patient Perceptions Differ Regarding Medical Management of Stone Disease. Journal of Urology, 2009, 182, 998-1004.	0.4	34
105	Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 292.e1-292.e9.	1.6	34
106	National trends and disparities of minimally invasive surgery for localized renal cancer, 2010 to 2015. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 182.e17-182.e27.	1.6	34
107	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 251-259.	2.2	33
108	Identification of the retrotrigonal layer as a key anatomical landmark during robotically assisted radical prostatectomy. BJU International, 2006, 98, 829-832.	2.5	32

#	Article	IF	CITATIONS
109	Retroperitoneal lymph node dissection after chemotherapy. BJU International, 2009, 104, 1404-1412.	2.5	31
110	Genderâ€specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU International, 2013, 112, 623-637.	2.5	31
111	Optical Reflectance Spectroscopy to Differentiate Benign From Malignant Renal Tumors at Surgery. Urology, 2009, 73, 178-181.	1.0	30
112	On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nature Reviews Urology, 2017, 14, 98-106.	3.8	30
113	Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer. Genome Biology, 2021, 22, 105.	8.8	29
114	Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU International, 2014, 113, 911-917.	2.5	28
115	Feasibility of laparoscopic approach in management of xanthogranulomatous pyelonephritis. Urology, 2006, 68, 711-714.	1.0	27
116	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. European Urology, 2014, 66, 379-385.	1.9	27
117	Hospital volume and outcomes of robotâ€assisted partial nephrectomy. BJU International, 2018, 121, 900-907.	2.5	27
118	Decreased expression of the human stem cell marker, Rex-1 (zfp-42) , in renal cell carcinoma. Carcinogenesis, 2006, 27, 499-507.	2.8	26
119	Laparoscopic adrenalectomy for large adrenal masses. Current Urology Reports, 2008, 9, 73-79.	2.2	26
120	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. BJU International, 2017, 119, 268-275.	2.5	26
121	Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer. Oncogene, 2020, 39, 1302-1317.	5.9	26
122	Associations between Hospital Volume and Outcomes of Robot-Assisted Radical Prostatectomy. Journal of Urology, 2020, 203, 926-932.	0.4	26
123	Renal ablative therapy: Radiofrequency ablation and cryoablation. Journal of Surgical Oncology, 2009, 100, 639-644.	1.7	25
124	Incidence and Predictors for Ipsilateral Hydronephrosis Following Ureteroscopic Lithotripsy. Urology, 2015, 86, 465-471.	1.0	25
125	Minimally Invasive Nephrectomy: The Influence of Laparoendoscopic Single-site Surgery on Patient Selection, Outcomes, and Morbidity. Urology, 2011, 77, 631-634.	1.0	23
126	Empiric antibiotics for an elevated prostateâ€specific antigen (<scp>PSA</scp>) level: a randomised, prospective, controlled multiâ€institutional trial. BJU International, 2013, 112, 925-929.	2.5	22

JAY D RAMAN

#	Article	IF	CITATIONS
127	Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcar carcinoma. Cancer, 2015, 121, 43-50.	4.1	22
128	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 113-120.	2.2	22
129	Repression of transcription factor AP-2 alpha by PPARÎ ³ reveals a novel transcriptional circuit in basal-squamous bladder cancer. Oncogenesis, 2019, 8, 69.	4.9	22
130	The Impact of Previous Ureteroscopic Tumor Ablation on Oncologic Outcomes After Radical Nephrouretectomy for Upper Urinary Tract Urothelial Carcinoma. Journal of Endourology, 2011, 25, 775-779.	2.1	21
131	Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e1-113.e7.	1.6	21
132	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 758-764.	1.6	21
133	Radiofrequency ablation for T1a tumors in a solitary kidney: promising intermediate oncologic and renal function outcomes. Canadian Journal of Urology, 2008, 15, 3980-5.	0.0	20
134	Renal tumor ablation is a function of patient selection and technique—Not the ablation technology. Cancer, 2008, 113, 2623-2626.	4.1	19
135	Peri-procedural povidone-iodine rectal preparation reduces microorganism counts and infectious complications following ultrasound-guided needle biopsy of the prostate. World Journal of Urology, 2014, 32, 905-909.	2.2	19
136	Endoscopic management of upper-tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2017, 17, 545-554.	2.4	19
137	Longitudinal Gender Disparity in Female Urology Resident Primary Authorship at an American Urological Association Sectional Meeting. Urology, 2017, 110, 40-44.	1.0	19
138	Hand-assisted laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. Journal of the Society of Laparoendoscopic Surgeons, 2006, 10, 432-8.	1.1	19
139	Bladder cancer following upper tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2008, 8, 75-85.	2.4	18
140	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. Urology, 2014, 84, 1134-1140.	1.0	18
141	Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems. International Journal of Molecular Sciences, 2019, 20, 2599.	4.1	18
142	ls sarcopenia and sarcopenic obesity associated with clinical and pathological outcomes in patients undergoing radical nephroureterectomy?. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 156.e17-156.e22.	1.6	17
143	Significant variability in 10â€year cumulative radiation exposure incurred on different surveillance regimens after surgery for pT1 renal cancers: yet another reason to standardize protocols?. BJU International, 2013, 111, 891-896.	2.5	16
144	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology, 2016, 94, 314.e1-314.e7.	1.0	16

#	Article	IF	CITATIONS
145	Complications Following Radical Nephroureterectomy. Current Urology Reports, 2016, 17, 36.	2.2	16
146	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e15-495.e22.	1.6	15
147	Impact of warm versus cold ischemia on renal function following partial nephrectomy. World Journal of Urology, 2015, 33, 351-357.	2.2	15
148	Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e11-88.e18.	1.6	15
149	Does Obesity Impact the Costs of Partial and Radical Nephrectomy?. Journal of Urology, 2008, 179, 1714-1718.	0.4	14
150	Conservative Nephron-Sparing Treatment of Upper-Tract Tumors. Current Urology Reports, 2013, 14, 102-108.	2.2	14
151	Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 258.e1-258.e6.	1.6	14
152	Critical analysis of 30 day complications following radical nephroureterectomy for upper tract urothelial carcinoma. Canadian Journal of Urology, 2014, 21, 7369-73.	0.0	14
153	Management and prevention of renal ablative therapy complications. World Journal of Urology, 2010, 28, 559-564.	2.2	13
154	Prostate magnetic resonance imaging: The truth lies in the eye of the beholder. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 159.e1-159.e5.	1.6	13
155	Predicted versus observed 30-day perioperative outcomes using the ACS NSQIP surgical risk calculator in patients undergoing partial nephrectomy for renal cell carcinoma. International Urology and Nephrology, 2018, 50, 1249-1256.	1.4	13
156	Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis. Minerva Urology and Nephrology, 2022, 74, .	2.5	12
157	The role of lymphadenectomy for upper tract urothelial carcinoma. Nature Reviews Urology, 2011, 8, 394-401.	3.8	11
158	Surgical management of bladder urothelial carcinoma with squamous differentiation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 429-433.	1.6	11
159	MicroRNA Expression Profiles in Upper Tract Urothelial Carcinoma Differentiate Tumor Grade, Stage, and Survival: Implications for Clinical Decision-Making. Urology, 2019, 123, 93-100.	1.0	11
160	Chronic Kidney Disease Epidemiology Collaboration Versus Modification of Diet in Renal Disease Equations for Renal Function Evaluation in Patients Undergoing Partial Nephrectomy. Journal of Urology, 2010, 184, 1867-1871.	0.4	10
161	Laparoendoscopic single-site pyeloplasty. Therapeutic Advances in Urology, 2011, 3, 141-149.	2.0	10
162	Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 614-621.	1.5	10

#	Article	IF	CITATIONS
163	Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center. Prostate International, 2018, 6, 110-114.	2.3	10
164	Preoperative urine culture is unnecessary in asymptomatic men prior to prostate needle biopsy. International Urology and Nephrology, 2018, 50, 21-24.	1.4	10
165	Incidence and preoperative predictors for major complications following radical nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1786-1793.	1.4	10
166	Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 933.e7-933.e12.	1.6	10
167	Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 737.e11-737.e16.	1.6	10
168	Impact of the evolving United States Preventative Services Task Force policy statements on incidence and distribution of prostate cancer over 15 years in a statewide cancer registry. Prostate International, 2021, 9, 12-17.	2.3	10
169	Kidney sparing surgery for upper-tract urothelial carcinoma. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2016, 68, 359-71.	3.9	10
170	Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies. Urology, 2005, 65, 931-936.	1.0	9
171	Comparison of Tissue Oxygenation Profiles Using 3 Different Methods of Vascular Control During Porcine Partial Nephrectomy. Urology, 2009, 74, 926-931.	1.0	9
172	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World Journal of Urology, 2015, 33, 1965-1972.	2.2	9
173	Strategies for prevention of ultrasound-guided prostate biopsy infections. Infection and Drug Resistance, 2016, Volume 9, 161-169.	2.7	9
174	Intracavitary therapies for upper tract urothelial carcinoma. Expert Review of Clinical Pharmacology, 2018, 11, 487-493.	3.1	9
175	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2019, 37, 2419-2427.	2.2	9
176	The Balance between Open and Robotic Training among Graduating Urology Residents—Does Surgical Technique Need Monitoring?. Journal of Urology, 2020, 203, 996-1002.	0.4	9
177	Kidney function outcomes following thermal ablation of small renal masses. World Journal of Nephrology, 2016, 5, 283.	2.0	9
178	Intratumoral Heterogeneity Promotes Collective Cancer Invasion through NOTCH1 Variation. Cells, 2021, 10, 3084.	4.1	9
179	Squamous Dysplasia of the Urinary Bladder. International Journal of Surgical Pathology, 2016, 24, 306-314.	0.8	8
180	Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1780-1785.	1.4	8

#	Article	IF	CITATIONS
181	Topical antiseptic at time of transrectal ultrasound prostate biopsy is associated with fewer severe clinical infections and improves antibiotic stewardship. Prostate International, 2021, 9, 185-189.	2.3	8
182	Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. Biomarkers in Medicine, 2008, 2, 165-180.	1.4	7
183	Phase One Pilot Study Using Magnetic Resonance Spectroscopy to Predict the Histology of Radiofrequency-Ablated Renal Tissue. European Urology, 2009, 55, 433-440.	1.9	7
184	OUTCOMES FOR PATIENTS WITH pTO DISEASE AFTER RADICAL NEPHROURETERECTOMY FOR UPPERâ€TRACT UROTHELIAL CARCINOMA. BJU International, 2009, 103, 3-4.	2.5	7
185	Advances in the management of upper tract urothelial carcinoma: improved endoscopic management through better diagnostics. Therapeutic Advances in Urology, 2018, 10, 421-429.	2.0	7
186	Accuracy of the NSQIP risk calculator for predicting complications following adrenalectomy. International Urology and Nephrology, 2019, 51, 1291-1295.	1.4	7
187	Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS. Scientific Reports, 2019, 9, 270.	3.3	7
188	Capturing Renal Cell Carcinoma Recurrences When Asymptomatic Improves Patient Survival. Clinical Genitourinary Cancer, 2019, 17, 132-138.	1.9	7
189	Androgen represses opioid growth factor receptor (OGFR) in human prostate cancer LNCaP cells and OGFR expression in human prostate cancer tissue. American Journal of Clinical and Experimental Urology, 2018, 6, 164-171.	0.4	7
190	Needlescopic ablation of small adrenal masses. Current Urology Reports, 2009, 10, 73-77.	2.2	6
191	RADICAL AND NONâ€RADICAL NEPHRECTOMY: NO PLACE FOR â€~SIMPLE'. BJU International, 2009, 103, 85	5-21556.	6
192	Has Laparoscopy Impacted the Indications for Adrenalectomy?. Current Urology Reports, 2010, 11, 132-137.	2.2	6
193	Variable Prostate-specific Antigen Management Patterns by Nonurologist Providers at a Tertiary Care Medical Center. Urology, 2011, 78, 244-248.	1.0	6
194	Survival outcomes for patients with localised upper tract urothelial carcinoma managed with nonâ€definitive treatment. BJU International, 2018, 121, 124-129.	2.5	6
195	Determinants of treatment in patients with stage IV renal cell carcinoma. BMC Urology, 2019, 19, 123.	1.4	6
196	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 496-505.	1.6	6
197	Tubulovillous adenoma in an Indiana pouch urinary diversion managed by endoscopic resection. International Journal of Urology, 2007, 14, 865-866.	1.0	5
198	Re: Excise, Ablate or Observe: The Small Renal Mass Dilemma—A Meta-Analysis and Review. Journal of Urology, 2008, 180, 1567-1568.	0.4	5

#	Article	IF	CITATIONS
199	Current status of ablative techniques for small renal masses. Expert Review of Anticancer Therapy, 2011, 11, 879-891.	2.4	5
200	Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2014, 14, 543-551.	2.4	5
201	Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection. Journal of Visualized Experiments, 2015, , .	0.3	5
202	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Journal of Urology, 2017, 198, 1269-1277.	0.4	5
203	Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. World Journal of Urology, 2017, 35, 943-949.	2.2	5
204	Topical rectal antiseptic at time of prostate biopsy: how a resident patient safety project has evolved into institutional practice. International Urology and Nephrology, 2018, 50, 1563-1568.	1.4	5
205	Urinary tract infection after radical cystectomy: a vexing problem despite prophylactic antibiotics. Translational Andrology and Urology, 2019, 8, S510-S513.	1.4	5
206	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World Journal of Urology, 2019, 37, 1631-1637.	2.2	5
207	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. Journal of Clinical Medicine, 2020, 9, 1218.	2.4	5
208	Single access laparoscopic nephrectomy. Indian Journal of Urology, 2008, 24, 457.	0.6	5
209	Perspectives on the Role of Biopsy for Management of T1 Renal Masses: Survey Results From Two Regional Quality Improvement Collaboratives. Urology, 2022, 165, 206-211.	1.0	5
210	Non-infectious complications following transrectal prostate needle biopsy – Outcomes from over 8000 procedures. Prostate International, 2022, 10, 158-161.	2.3	5
211	Re: Single Port Transumbilical (E-NOTES) Donor Nephrectomy. Journal of Urology, 2009, 181, 418-419.	0.4	4
212	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	2.2	4
213	Serum carotenoid and retinol levels in African-Caribbean Tobagonian men with high prostate cancer risk in comparison with African-American men. British Journal of Nutrition, 2017, 117, 1128-1136.	2.3	4
214	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e1-343.e8.	1.6	4
215	A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study). Urologic Oncology: Seminars and Original Investigations, 2019, 37, 577.e1-577.e7. 	1.6	4
216	Adrenalectomy: should urologists not be doing more?. International Urology and Nephrology, 2020, 52, 197-204.	1.4	4

#	Article	IF	CITATIONS
217	Endoscopic Closure of a Large Rectovesical Fistula Following Robotic Prostatectomy. Journal of Endourology Case Reports, 2020, 6, 139-142.	0.3	4
218	Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors. Journal of Kidney Cancer and VHL, 2020, 7, 1-5.	1.0	4
219	Exploration of treatment options for the management of stage I testicular seminoma. Expert Review of Anticancer Therapy, 2008, 8, 1081-1090.	2.4	3
220	Are Urology Residents Adequately Exposed to Conservative Therapies for Managing Small Renal Masses?. Journal of Endourology, 2011, 25, 129-133.	2.1	3
221	Is LESS partial nephrectomy feasible for most urologists?. Nature Reviews Urology, 2013, 10, 260-261.	3.8	3
222	Incarcerated Right Lateral Trocar-Site Hernia as a Rare Complication of Robot-Assisted Laparoscopic Prostatectomy. Journal of Endourology Case Reports, 2017, 3, 155-157.	0.3	3
223	Incidence and histologic features of mixed renal tumors. Journal of Surgical Oncology, 2018, 117, 430-433.	1.7	3
224	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2019, 5, 97-103.	3.1	3
225	The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States. Cancer Management and Research, 2020, Volume 12, 9825-9836.	1.9	3
226	Peri-operative morbidity and mortality in a modern series of patients treated with cytoreductive nephrectomy (CN) at five centers Journal of Clinical Oncology, 2021, 39, 268-268.	1.6	3
227	Widely Variable Parental Leave Practices for Urology Residency Programs in the United States. Urology, 2021, 153, 81-86.	1.0	3
228	THE PRESENCE OF VASAL VESSELS IN MEN WITH CONGENITAL BILATERAL ABSENCE OF THE VAS DEFERENS. Journal of Urology, 2004, 172, 1941-1943.	0.4	2
229	Editorial Comment. Urology, 2009, 73, 1065-1066.	1.0	2
230	Optimizing and integrating cisplatin-based chemotherapy across the disease spectrum. Nature Reviews Urology, 2018, 15, 139-140.	3.8	2
231	Hemostatic agent use during partial nephrectomy: trends, outcomes, and associated costs. International Urology and Nephrology, 2020, 52, 2073-2078.	1.4	2
232	Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. World Journal of Urology, 2021, 39, 491-500.	2.2	2
233	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e15-788.e21.	1.6	2
234	The Consequences of Inadvertent Radical Nephrectomy in the Treatment of Upper Tract Urothelial Carcinoma. Urology, 2021, 154, 127-135.	1.0	2

#	Article	IF	CITATIONS
235	Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy. Journal of Kidney Cancer and VHL, 2020, 7, 20-25.	1.0	2
236	Measuring renal function before kidney surgery — evolving towards precision in medicine. Nature Reviews Urology, 2022, 19, 450-451.	3.8	2
237	Re: Prognostic Value of MET, RON and Histoprognostic Factors for Urothelial Carcinoma in the Upper Urinary Tract. Journal of Urology, 2008, 180, 1183-1184.	0.4	1
238	SINGLE INCISION (KEYHOLE) UMBILICAL UROLOGIC SURGERY: INITIAL CLINICAL EXPERIENCE. Journal of Urology, 2008, 179, 237-238.	0.4	1
239	IMPACT OF TUMOR LOCATION ON PROGNOSIS FOR UPPER- TRACT UROTHELIAL CARCINOMA: OUTCOMES FROM OVER 1300 PATIENTS. Journal of Urology, 2008, 179, 289-289.	0.4	1
240	Renal neuroectodermal tumour presenting with hematuria. Journal of Radiology Case Reports, 2010, 4, 12-20.	0.4	1
241	1486 DURABLE ONCOLOGIC OUTCOMES FOLLOWING RADIOFREQUENCY ABLATION (RFA): EXPERIENCE FROM TREATING 243 SMALL RENAL MASSES OVER 7.5 YEARS. Journal of Urology, 2010, 183, .	0.4	1
242	Editorial Comment. Urology, 2011, 77, 568-569.	1.0	1
243	Editorial Comment. Journal of Urology, 2011, 186, 1848-1848.	0.4	1
244	ls perinephric drainage essential after partial nephrectomy?. Nature Reviews Urology, 2011, 8, 594-595.	3.8	1
245	Clearing murky water — a guideline-based approach to haematuria. Nature Reviews Urology, 2016, 13, 243-244.	3.8	1
246	Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer. Translational Andrology and Urology, 2018, 7, S732-S734.	1.4	1
247	Bladder Chemoprophylaxis Following Ureterorenoscopy in Patients with Upper Tract Urothelial Carcinoma. European Urology Focus, 2021, , .	3.1	1
248	Preoperative metastatic disease burden to predict overall survival following cytoreductive nephrectomy independent of IMDC risk category Journal of Clinical Oncology, 2020, 38, 652-652.	1.6	1
249	Management of Low-grade Upper Tract Urothelial Carcinoma: An Unmet Need. Reviews in Urology, 2020, 22, 1-8.	0.9	1
250	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers, 2022, 14, 1781.	3.7	1
251	Prognostic markers and targeted therapies for renal cell carcinoma. Future Oncology, 2009, 5, 197-205.	2.4	0
252	Re: Effectiveness of Antibiotics Given to Asymptomatic Men for an Increased Prostate Specific Antigen. Journal of Urology, 2009, 182, 396-397.	0.4	0

#	Article	IF	CITATIONS
253	Editorial <scp>C</scp> omment to <scp>R</scp> enal pelvic villous adenoma presented with mucusuria: <scp>R</scp> eport of a case and literature review. International Journal of Urology, 2013, 20, 250-250.	1.0	0
254	Editorial Comment from <scp>D</scp> r <scp>K</scp> aag and <scp>D</scp> r <scp>R</scp> aman to Obesity and prognosis in muscleâ€invasive bladder cancer: The continuing controversy. International Journal of Urology, 2014, 21, 1113-1113.	1.0	0
255	Editorial Comment. Urology, 2014, 84, 284.	1.0	0
256	Systemic chemotherapy and radical nephroureterectomy. International Urology and Nephrology, 2015, 47, 709-710.	1.4	0
257	Editorial Comment. Urology, 2017, 102, 35-36.	1.0	0
258	Association Between Hospitals' Risk-Adjusted Emergency Department Visits and Survival and Costs in Kidney Cancer Patients Undergoing Nephrectomy. Clinical Genitourinary Cancer, 2019, 17, e650-e657.	1.9	0
259	Adjuvant and ablative therapies for low-risk UTUC: avenues to enhance kidney preservation. Nature Reviews Urology, 2020, 17, 433-434.	3.8	0
260	Can preoperative imaging characteristics predict pT3 bladder cancer following cystectomy?. World Journal of Urology, 2021, 39, 1941-1945.	2.2	0
261	Microhematuria: AUA/SUFU Guideline. Letter Journal of Urology, 2021, 205, 1533-1534.	0.4	0
262	Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 433.e9-433.e15.	1.6	0
263	Potential Winners and Losers: Understanding How the Oncology Care Model May Differentially Affect Hospitals. JCO Oncology Practice, 2021, 17, e1150-e1161.	2.9	0
264	Extracorporeal Shock Wave Lithotripsy for Ureteral Stones. , 2010, , 469-477.		0
265	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma Journal of Clinical Oncology, 2012, 30, 281-281.	1.6	0
266	Single-Port Laparoscopy: Issues and Complications. , 2013, , 313-322.		0
267	Multi-institutional evaluation of the prognostic significance of altered mammalian target of rapamycin (mTOR) pathway biomarkers in upper-tract urothelial carcinoma (UTUC) Journal of Clinical Oncology, 2014, 32, 323-323.	1.6	0
268	Significant methodologic variations in calculating renal function changes following kidney tumor surgery: A quality reporting issue?. World Journal of Clinical Oncology, 2015, 6, 89.	2.3	0
269	Multi-institutional validation of the predictive value of Ki-67 in patients with high-grade urothelial carcinoma of the upper urinary tract Journal of Clinical Oncology, 2015, 33, 371-371.	1.6	0
270	Multi-institutional validation of the predictive value of Ki-67 in patients with high-grade urothelial carcinoma of the upper urinary tract Journal of Clinical Oncology, 2015, 33, 4569-4569.	1.6	0

#	Article	IF	CITATIONS
271	Predictive models for improved prognostication and selection of neoadjuvant and adjuvant systemic chemotherapy in upper tract urothelial cell carcinoma Journal of Clinical Oncology, 2016, 34, 456-456.	1.6	0
272	Upper Urinary Tract Carcinoma In Situ. , 2018, , 85-95.		0
273	Novel transgenic knockout model of basal-squamous bladder cancer Journal of Clinical Oncology, 2018, 36, 459-459.	1.6	0
274	Concordance between MRI fusion versus TRUS prostate biopsy and final pathology at radical prostatectomy: Data from the PURC Journal of Clinical Oncology, 2020, 38, 354-354.	1.6	0
275	Patient Perceptions Regarding Routine Oncologic Follow-Up for Urologic Malignancies. Clinical Genitourinary Cancer, 2022, 20, 298-298.e11.	1.9	0
276	RE: "Transperineal Prostate Biopsy is Associated With Lower Tissue Core Pathogen Burden Relative to Transrectal Biopsy: Mechanistic Underpinnings for Lower Infection Risk in the Transperineal Approach― Urology, 2022, , .	1.0	0